Aminologics Co.Ltd Asset Resilience Ratio
Aminologics Co.Ltd asset resilience ratio. Aminologics Co.Ltd (074430) has an Asset Resilience Ratio of 33.62% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Aminologics Co.Ltd (074430) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aminologics Co.Ltd (2008–2025)
Asset resilience ratio of Aminologics Co.Ltd from 2008 to 2025. This chart shows how Aminologics Co.Ltd's Asset Resilience Ratio has changed over time. Read 074430 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aminologics Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 074430 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩30.16 Billion | 33.62% |
| Total Liquid Assets | ₩30.16 Billion | 33.62% |
Asset Resilience Insights
- Very High Liquidity: Aminologics Co.Ltd maintains exceptional liquid asset reserves at 33.62% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Aminologics Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Aminologics Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
GeneBioTech Co. Ltd
KQ:086060 |
Pharmaceuticals | 22.68% |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250 |
Pharmaceuticals | 6.87% |
|
ST Pharm Co.Ltd
KQ:237690 |
Pharmaceuticals | 7.72% |
|
NatureCell Co.Ltd
KQ:007390 |
Pharmaceuticals | 0.00% |
|
Oscotec Inc
KQ:039200 |
Pharmaceuticals | 66.73% |
|
Komipharm International Co. Ltd
KQ:041960 |
Pharmaceuticals | 0.00% |
|
Mezzion Pharma Co.Ltd
KQ:140410 |
Pharmaceuticals | 0.00% |
|
Aprogen Healthcare & Games Inc
KQ:109960 |
Pharmaceuticals | 6.55% |
Aminologics Co.Ltd Asset Resilience Ratio by Year (2008–2025)
Aminologics Co.Ltd asset resilience ratio by year from 2008 to 2025. The table below shows the annual Asset Resilience Ratio data for Aminologics Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.45% | ₩36.58 Billion ≈ $24.79 Million |
₩84.18 Billion ≈ $57.05 Million |
-18.85pp |
| 2024-12-31 | 62.30% | ₩35.38 Billion ≈ $23.98 Million |
₩56.79 Billion ≈ $38.49 Million |
+12.89pp |
| 2023-12-31 | 49.42% | ₩28.50 Billion ≈ $19.31 Million |
₩57.67 Billion ≈ $39.08 Million |
-3.19pp |
| 2022-12-31 | 52.60% | ₩29.24 Billion ≈ $19.81 Million |
₩55.58 Billion ≈ $37.67 Million |
+13.27pp |
| 2021-12-31 | 39.34% | ₩25.66 Billion ≈ $17.39 Million |
₩65.24 Billion ≈ $44.21 Million |
-2.88pp |
| 2020-12-31 | 42.21% | ₩25.38 Billion ≈ $17.20 Million |
₩60.13 Billion ≈ $40.75 Million |
-0.61pp |
| 2019-12-31 | 42.83% | ₩24.74 Billion ≈ $16.77 Million |
₩57.77 Billion ≈ $39.15 Million |
+4.33pp |
| 2018-12-31 | 38.50% | ₩21.89 Billion ≈ $14.83 Million |
₩56.86 Billion ≈ $38.53 Million |
+2.98pp |
| 2017-12-31 | 35.51% | ₩17.53 Billion ≈ $11.88 Million |
₩49.37 Billion ≈ $33.46 Million |
+5.55pp |
| 2016-12-31 | 29.96% | ₩14.69 Billion ≈ $9.96 Million |
₩49.03 Billion ≈ $33.22 Million |
+29.96pp |
| 2015-12-31 | 0.00% | ₩-220.00 ≈ $-0.15 |
₩55.03 Billion ≈ $37.29 Million |
-0.06pp |
| 2014-12-31 | 0.06% | ₩21.34 Million ≈ $14.46K |
₩38.63 Billion ≈ $26.18 Million |
-0.55pp |
| 2013-12-31 | 0.60% | ₩289.85 Million ≈ $196.43K |
₩48.20 Billion ≈ $32.67 Million |
-12.78pp |
| 2012-12-31 | 13.38% | ₩7.05 Billion ≈ $4.78 Million |
₩52.70 Billion ≈ $35.71 Million |
-14.27pp |
| 2011-12-31 | 27.65% | ₩23.28 Billion ≈ $15.77 Million |
₩84.17 Billion ≈ $57.04 Million |
+8.19pp |
| 2010-12-31 | 19.46% | ₩11.45 Billion ≈ $7.76 Million |
₩58.86 Billion ≈ $39.89 Million |
+11.68pp |
| 2008-12-31 | 7.78% | ₩5.15 Billion ≈ $3.49 Million |
₩66.21 Billion ≈ $44.87 Million |
-- |
About Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more